

Krystal Biotech Pipeline

	Product	Protein	Indication	Discovery	Preclinical	Phase 1/2	Phase 3	Commercial
Dermatology	B-VEC ^{†‡•Δ‡§}	Type VII collagen	Dystrophic Epidermolysis Bullosa	→				BLA accepted and under review
	KB105 ^{†‡•‡}	Transglutaminase 1 (TGM1)	TGM1-deficient ARCI	→				
	KB104 [‡]	Serine Peptidase Inhibitor Kazal Type 5 (SPINK5)	Netherton Syndrome	→				
	KB1XX	Undisclosed Programs		→				
Respiratory	KB5XX	Vector Encoded Antibodies	Chronic Skin Conditions	→				
	KB407 ^{†‡‡}	Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)	Cystic Fibrosis	→				
	KB408	Alpha-1 antitrypsin (AATD)	alpha-1 antitrypsin deficiency	→				
	KB4XX	Undisclosed Programs		→				

All pipeline compounds are investigational. All pipeline compounds are wholly owned.

†: FDA Orphan Drug Designation;
‡: FDA Rare Pediatric Disease Designation;
•: Fast-track Designation;

Δ: FDA RMAT designation;
‡: EMA Orphan Drug Designation;
§: EMA PRIME Designation.

Rare disease

More prevalent conditions

Jeune Aesthetics Pipeline

	Product	Gene	Indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Commercial
Aesthetics	KB301	Type III collagen	TBD	→					
	KB302	Type I collagen	TBD	→					
	KB303	Elastin	TBD	→					
	KB304	Type III collagen & Elastin	TBD	→					
	KB305	Type IV collagen	TBD	→					

All pipeline compounds are investigational, being evaluated in clinical or pre-clinical studies. All pipeline compounds are wholly owned.